The bound structure of receptors with ligands is considered a therapeutic target for breast cancer treatment and we have docked the native ligand as well, to check how our proposed compound advances and found that ziprasidone has better binding affinities which are shown in the ST2 (Supplementary Table 2) and SF1 (Supplementary Fig. 1). Here, SF1 is linked to breast cancer.